CYP17 polymorphisms and prostate cancer outcomes. - Wikidata - wikimedia - TriplyDB

CYP17 polymorphisms and prostate cancer outcomes.

CYP17 polymorphisms and prostate cancer outcomes.

http://www.wikidata.org/entity/Q33884273

about

Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.Genetic variation: effect on prostate cancer.Genomic and epigenomic alterations in prostate cancer.Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.Coffee and tea consumption in relation to prostate cancer prognosis.Statin use in relation to prostate cancer outcomes in a population-based patient cohort study.Molecular genetics of prostate cancer: emerging appreciation of genetic complexity.Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.Androgen dynamics and serum PSA in patients treated with abiraterone acetate.Prostate cancer risk variants are not associated with disease progression.Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness.Quantitative assessment of the association between CYP17 rs743572 polymorphism and prostate cancer risk.Association of variants in genes involved in environmental chemical metabolism and risk of cryptorchidism and hypospadias.

P2860

Q26766638-701811E0-C3D6-4E15-BFC8-AE23660AD74D Q30499412-A7F49F96-4149-4E93-B6DB-CDB70D4DB5A8 Q30504100-696694F6-883A-45C6-94EB-446D8EE63A6D Q33752605-D1534C90-416D-42B5-BA7E-D7C6FB492099 Q34663656-F5D7AF0B-FC13-4DB3-9CD9-D0568B8C3E9E Q36374578-A1C5B6A2-35E9-45FB-BAE0-6B4489DAAA27 Q37139054-FFA9B833-E5F4-4021-9729-2203C449D5CC Q37383978-4C7BB69C-B830-46B4-9705-8947B74C61FD Q37667939-FD764AA6-C7A3-4F2D-8631-ABDCA95F65EF Q37972706-20DB2E90-9A6C-4FF6-B51C-D23A7EAE20F5 Q38620751-D99C7DBC-B85C-4635-81B7-DA003C1A38F4 Q39588931-5C034947-2680-4A79-8916-DB37C93A03C9 Q39757112-04F2C93D-A468-4BD9-AA5F-4D7091418DF4 Q42370692-E1BBBCC6-020A-4BDE-82D2-A0F90D103EF3 Q43845691-3C3810FA-C2A7-4365-9929-536AA19B9A87 Q52625915-F78F7963-56BA-4CA4-AF66-2D2ED03928A9

P2860

CYP17 polymorphisms and prostate cancer outcomes.

http://www.wikidata.org/entity/Q33884273

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

CYP17 polymorphisms and prostate cancer outcomes.

@ast

CYP17 polymorphisms and prostate cancer outcomes.

@en

type

label

CYP17 polymorphisms and prostate cancer outcomes.

@ast

CYP17 polymorphisms and prostate cancer outcomes.

@en

prefLabel

CYP17 polymorphisms and prostate cancer outcomes.

@ast

CYP17 polymorphisms and prostate cancer outcomes.

@en

P1433

Q33884273-D68BD0CB-8AC9-455B-8CE7-0FB239799DCB

P1476

Q33884273-45DEE5A2-5F56-465B-8211-EDB7911A6D1E

P2093

Q33884273-09BD27C2-6F02-40A5-8F83-EC131B6C39AC

Q33884273-4304BA71-C2B1-4C55-8D69-8EDE05C882D1

Q33884273-4CBB69DA-5A75-412D-992F-F6006DF97EA6

Q33884273-5464B302-707A-4C0A-9045-E3616122BD1E

Q33884273-77CF6F0B-7767-452B-BDE8-93ED034068D0

Q33884273-AF27BBB8-F485-4173-B10E-69DFF5590CF4

Q33884273-D78954E9-AED6-4DFB-929B-5B47CF734C3D

P2860

Q33884273-062AE9BF-15FC-4F0E-9340-087BC243F6D4

Q33884273-0D27411F-F945-4A59-94E7-5F2155DD94EF

Q33884273-10930436-35E6-4366-A976-786754EDB253

Q33884273-30C52130-EB34-4CE5-B7F7-DC041410726C

Q33884273-3E59C64B-E8BD-4948-B204-73A63FDA99AB

Q33884273-4260E6F5-88EE-4B47-AFC7-598F94BB6718

Q33884273-492F47D5-9FDA-424B-9A75-9435FDE04369

Q33884273-4C10BF06-C74A-470A-B2FE-E1CF4607C5EB

Q33884273-4E7990E3-CF02-43AB-8E23-D6B659D3ADA2

Q33884273-6D471173-AC94-4EAD-B94F-876EF32621BB

P304

Q33884273-674438A5-A573-4700-8252-A1375F1F3332

P31

Q33884273-D3A50FC7-6401-4918-A913-CBCDB7BB43EA

P356

Q33884273-979A1D71-7487-4D26-99FE-192F7A7B5D06

P433

Q33884273-06776B61-A6D3-438E-874A-AAAE574C9622

P478

Q33884273-7E0FFA74-88AA-4614-8C8D-AA148FBFEF57

P50

Q33884273-DD5DD308-3BA1-4822-BB1D-B0A2A7179561

P577

Q33884273-925DFD3A-CB8A-4ACD-BA1D-DF6651B99CA8

P5875

Q33884273-899DD022-75C5-4F44-B187-EC14B2CB9F7B

P698

Q33884273-CFE4EE8C-56C0-4DC3-B4F7-3CC93052CCD6

P932

Q33884273-FFD61F85-8576-41A8-8360-4444B54E5598

P356

P1433

P1476

CYP17 polymorphisms and prostate cancer outcomes.

@en

P2093

Daniel W Lin

http://www.w3.org/2001/XMLSchema#string

Erika M Kwon

http://www.w3.org/2001/XMLSchema#string

Janet L Stanford

http://www.w3.org/2001/XMLSchema#string

Jonathan L Wright

http://www.w3.org/2001/XMLSchema#string

Joseph S Koopmeiners

http://www.w3.org/2001/XMLSchema#string

Suzanne Kolb

http://www.w3.org/2001/XMLSchema#string

Ziding Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis.

Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Vasectomy and risk of prostate cancer.

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.

A polymorphism in the CYP17 gene and risk of prostate cancer.

P304

1094-1101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.21143

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Elaine Ostrander

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44631164

http://www.w3.org/2001/XMLSchema#string

P698

20503394

http://www.w3.org/2001/XMLSchema#string

P932

2878282

http://www.w3.org/2001/XMLSchema#string